Crossmark Global Holdings Inc. Buys 44,828 Shares of CVS Health Corporation $CVS

Key Points

• Crossmark Global Holdings increased its CVS Health stake by 11.3% in the third quarter, purchasing 44,828 additional shares and bringing its total holdings to 440,645 shares valued at approximately $37.8 million.
• Institutional investors collectively own 80.66% of CVS Health, while several other firms—including Robeco and Carnegie Investment Counsel—also added to their positions during the quarter.
• CVS reported quarterly results above expectations, with $2.58 in EPS and $106.1 billion in revenue; analysts maintain a “Moderate Buy” consensus and an average price target of $107.80. The company also declared a $0.665 quarterly dividend, yielding about 2.8%.

Crossmark Global Holdings Inc. boosted its stake in CVS Health Corporation (NYSE:CVS - Free Report) by 11.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 440,645 shares of the pharmacy operator's stock after purchasing an additional 44,828 shares during the period. Crossmark Global Holdings Inc.'s holdings in CVS Health were worth $37,759,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Guardian Partners Inc. raised its stake in shares of CVS Health by 12.4% during the third quarter. Guardian Partners Inc. now owns 5,196 shares of the pharmacy operator's stock valued at $445,000 after acquiring an additional 574 shares during the last quarter. Strengthening Families & Communities LLC boosted its holdings in shares of CVS Health by 8.3% during the third quarter. Strengthening Families & Communities LLC now owns 32,998 shares of the pharmacy operator's stock worth $2,828,000 after purchasing an additional 2,536 shares during the period. Axecap Investments LLC bought a new stake in shares of CVS Health in the third quarter worth about $2,814,000. Carnegie Investment Counsel grew its stake in shares of CVS Health by 3.6% in the third quarter. Carnegie Investment Counsel now owns 39,461 shares of the pharmacy operator's stock worth $3,381,000 after purchasing an additional 1,357 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its stake in shares of CVS Health by 4.1% in the third quarter. Robeco Institutional Asset Management B.V. now owns 2,091,736 shares of the pharmacy operator's stock worth $179,241,000 after purchasing an additional 82,976 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding access through smaller, pharmacy-focused store formats in underserved communities. The strategy is intended to align locations with prescription demand, improve operating efficiency and support pharmacy growth. How Small Pharmacy Expansion Will Impact CVS Health Investors
• Positive Sentiment: MinuteClinic opened three new Massachusetts locations, including the first in Boston, broadening CVS’s retail healthcare footprint and potentially increasing patient traffic and service revenue. MinuteClinic Opens Three New Retail Medical Clinics
• Positive Sentiment: CVS is seeking to capture customers from Walgreens and Rite Aid as competitors close stores. The opportunity could support prescription volumes and strengthen CVS’s local market share. CVS Targets Former Walgreens and Rite Aid Customers
• Positive Sentiment: Aetna is streamlining prior authorizations, reporting that more than 95% of eligible requests are approved within 24 hours. Faster approvals may improve member experience and reduce administrative friction, although the direct financial effect is not yet quantified. How CVS Aetna Is Reducing Administrative Burden

CVS Health Stock Performance

Shares of CVS opened at $93.62 on Thursday. The company has a 50-day simple moving average of $91.68 and a two-hundred day simple moving average of $93.63. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market capitalization of $119.74 billion, a PE ratio of 24.77, a price-to-earnings-growth ratio of 0.88 and a beta of 0.60. CVS Health Corporation has a one year low of $69.51 and a one year high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.71. The company had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The firm's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, analysts anticipate that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be given a dividend of $0.6650 per share. This represents a $2.66 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Thursday, October 22nd. CVS Health's dividend payout ratio is 70.37%.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CVS. Wells Fargo & Company boosted their price target on CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a report on Monday, July 13th. Sanford C. Bernstein reiterated an "outperform" rating and issued a $112.00 price objective on shares of CVS Health in a report on Wednesday, September 9th. UBS Group reiterated a "buy" rating on shares of CVS Health in a research report on Tuesday, September 22nd. HSBC reiterated a "hold" rating and issued a $103.00 price objective on shares of CVS Health in a research report on Monday, July 6th. Finally, Leerink Partners reduced their target price on CVS Health from $119.00 to $112.00 and set an "outperform" rating on the stock in a research note on Monday, October 12th. Twenty equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, CVS Health presently has an average rating of "Moderate Buy" and a consensus price target of $107.80.

CVS Health Profile

CVS Health Corporation NYSE: CVS is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company's Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.